EMAP II: A modulator of neovascularization in the developing lung

Maegaret Schwarz, Matt Lee, Fangrong Zhang, Jingsong Zhao, Yangsun Jin, Susan Smith, Janki Bhuva, David Stern, David Warburton, Vaughn Starnes

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Neovascularization is a key regulatory process in fetal growth and development. Although factors promoting growth and development of the pulmonary vasculature have been investigated, nothing is known regarding the molecular mechanisms that may counteract these stimuli. Endothelial monocyte- activating polypeptide (EMAP) II has recently been identified as an antiangiogenic factor in tumor vascular development. We postulated that EMAP II is a putative negative modulator of lung vascular growth. EMAP II mRNA and protein decrease fivefold (P < 0.01) as the developing lungs in the fetal mouse progress from having poor vascularization (day 14) to having complete vascular development at term (day 18.5). EMAP II protein expression continues to remain low throughout postnatal life and into adulthood, with the exception of a surge that correlates with microvascular maturation. Furthermore, through the use of in situ hybridization and immunohistochemistry, EMAP II is localized throughout the lung, with significant expression in the submyoepithelial area during the early stages of lung development when there is minimal vascular development. In contrast, EMAP II is distributed around the large vessels during the end of vascular development, suggesting that EMAP II modulates the neovascularization process. We speculate that EMAP II is a director of neovascularization in the developing lung.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume276
Issue number2 20-2
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Lung
Blood Vessels
Fetal Development
Growth and Development
small inducible cytokine subfamily E, member 1
In Situ Hybridization
Proteins
Immunohistochemistry
Messenger RNA
Growth
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Cell Biology
  • Physiology
  • Physiology (medical)

Cite this

Schwarz, M., Lee, M., Zhang, F., Zhao, J., Jin, Y., Smith, S., ... Starnes, V. (1999). EMAP II: A modulator of neovascularization in the developing lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 276(2 20-2).

EMAP II : A modulator of neovascularization in the developing lung. / Schwarz, Maegaret; Lee, Matt; Zhang, Fangrong; Zhao, Jingsong; Jin, Yangsun; Smith, Susan; Bhuva, Janki; Stern, David; Warburton, David; Starnes, Vaughn.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 276, No. 2 20-2, 02.1999.

Research output: Contribution to journalArticle

Schwarz, M, Lee, M, Zhang, F, Zhao, J, Jin, Y, Smith, S, Bhuva, J, Stern, D, Warburton, D & Starnes, V 1999, 'EMAP II: A modulator of neovascularization in the developing lung', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 276, no. 2 20-2.
Schwarz, Maegaret ; Lee, Matt ; Zhang, Fangrong ; Zhao, Jingsong ; Jin, Yangsun ; Smith, Susan ; Bhuva, Janki ; Stern, David ; Warburton, David ; Starnes, Vaughn. / EMAP II : A modulator of neovascularization in the developing lung. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 1999 ; Vol. 276, No. 2 20-2.
@article{8cc8a5c1995a4b7083a388672d050f58,
title = "EMAP II: A modulator of neovascularization in the developing lung",
abstract = "Neovascularization is a key regulatory process in fetal growth and development. Although factors promoting growth and development of the pulmonary vasculature have been investigated, nothing is known regarding the molecular mechanisms that may counteract these stimuli. Endothelial monocyte- activating polypeptide (EMAP) II has recently been identified as an antiangiogenic factor in tumor vascular development. We postulated that EMAP II is a putative negative modulator of lung vascular growth. EMAP II mRNA and protein decrease fivefold (P < 0.01) as the developing lungs in the fetal mouse progress from having poor vascularization (day 14) to having complete vascular development at term (day 18.5). EMAP II protein expression continues to remain low throughout postnatal life and into adulthood, with the exception of a surge that correlates with microvascular maturation. Furthermore, through the use of in situ hybridization and immunohistochemistry, EMAP II is localized throughout the lung, with significant expression in the submyoepithelial area during the early stages of lung development when there is minimal vascular development. In contrast, EMAP II is distributed around the large vessels during the end of vascular development, suggesting that EMAP II modulates the neovascularization process. We speculate that EMAP II is a director of neovascularization in the developing lung.",
author = "Maegaret Schwarz and Matt Lee and Fangrong Zhang and Jingsong Zhao and Yangsun Jin and Susan Smith and Janki Bhuva and David Stern and David Warburton and Vaughn Starnes",
year = "1999",
month = "2",
language = "English (US)",
volume = "276",
journal = "American Journal of Physiology - Lung Cellular and Molecular Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "2 20-2",

}

TY - JOUR

T1 - EMAP II

T2 - A modulator of neovascularization in the developing lung

AU - Schwarz, Maegaret

AU - Lee, Matt

AU - Zhang, Fangrong

AU - Zhao, Jingsong

AU - Jin, Yangsun

AU - Smith, Susan

AU - Bhuva, Janki

AU - Stern, David

AU - Warburton, David

AU - Starnes, Vaughn

PY - 1999/2

Y1 - 1999/2

N2 - Neovascularization is a key regulatory process in fetal growth and development. Although factors promoting growth and development of the pulmonary vasculature have been investigated, nothing is known regarding the molecular mechanisms that may counteract these stimuli. Endothelial monocyte- activating polypeptide (EMAP) II has recently been identified as an antiangiogenic factor in tumor vascular development. We postulated that EMAP II is a putative negative modulator of lung vascular growth. EMAP II mRNA and protein decrease fivefold (P < 0.01) as the developing lungs in the fetal mouse progress from having poor vascularization (day 14) to having complete vascular development at term (day 18.5). EMAP II protein expression continues to remain low throughout postnatal life and into adulthood, with the exception of a surge that correlates with microvascular maturation. Furthermore, through the use of in situ hybridization and immunohistochemistry, EMAP II is localized throughout the lung, with significant expression in the submyoepithelial area during the early stages of lung development when there is minimal vascular development. In contrast, EMAP II is distributed around the large vessels during the end of vascular development, suggesting that EMAP II modulates the neovascularization process. We speculate that EMAP II is a director of neovascularization in the developing lung.

AB - Neovascularization is a key regulatory process in fetal growth and development. Although factors promoting growth and development of the pulmonary vasculature have been investigated, nothing is known regarding the molecular mechanisms that may counteract these stimuli. Endothelial monocyte- activating polypeptide (EMAP) II has recently been identified as an antiangiogenic factor in tumor vascular development. We postulated that EMAP II is a putative negative modulator of lung vascular growth. EMAP II mRNA and protein decrease fivefold (P < 0.01) as the developing lungs in the fetal mouse progress from having poor vascularization (day 14) to having complete vascular development at term (day 18.5). EMAP II protein expression continues to remain low throughout postnatal life and into adulthood, with the exception of a surge that correlates with microvascular maturation. Furthermore, through the use of in situ hybridization and immunohistochemistry, EMAP II is localized throughout the lung, with significant expression in the submyoepithelial area during the early stages of lung development when there is minimal vascular development. In contrast, EMAP II is distributed around the large vessels during the end of vascular development, suggesting that EMAP II modulates the neovascularization process. We speculate that EMAP II is a director of neovascularization in the developing lung.

UR - http://www.scopus.com/inward/record.url?scp=6544280144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6544280144&partnerID=8YFLogxK

M3 - Article

C2 - 9950900

AN - SCOPUS:6544280144

VL - 276

JO - American Journal of Physiology - Lung Cellular and Molecular Physiology

JF - American Journal of Physiology - Lung Cellular and Molecular Physiology

SN - 1040-0605

IS - 2 20-2

ER -